Hepatitis A News and Research

RSS

Hepatitis A (formerly known as ''infectious hepatitis'') is an acute infectious disease of the liver caused by the hepatitis A virus (HAV), which is most commonly transmitted by the fecal-oral route via contaminated food or drinking water.

Research on SARS-CoV-2 spike protein may lead to new vaccines and treatments

The virus that causes COVID-19 is studded on its exterior with "spike proteins," a key component in its ability to infect human cells. Two University of Georgia researchers, Rob Woods and Parastoo Azadi, are investigating the proteins and sugars on the surface of the virus with the goal of finding information that could lead to vaccines and therapeutics.

28 Apr 2020

Research provides insights into how Zika virus can spread through sexual contact

Zika virus is capable of replicating and spreading infectious particles within the outermost cells lining the vaginal tract, according to new research. The findings provide the first molecular-level insights into how the virus can move from person to person through sexual contact.

27 Apr 2020

Study can lead the way to new treatment methods for hepatitis C in infants

Only about five per cent of the babies born to mothers with hepatitis C are themselves infected by the disease.

27 Apr 2020

Research shows how the immune system reacts to hepatitis C viruses

If a virus penetrates a cell, the immune system reacts immediately and produces the signaling protein interferon.

24 Apr 2020

Indiana Network for Population Health aims to address the social determinants of health

The Indiana Network for Population Health has been launched by the Regenstrief Institute and collaborators, including the State of Indiana, Indiana University and the Indiana Health Information Exchange, to provide the secure exchange of comprehensive data -- especially information on social determinants of health such as housing stability and access to nutritious food -- to researchers, policy makers, healthcare providers and others on the front lines fighting opioid and other addictions.

23 Apr 2020

Using 'own' immune cells to fight infectious diseases including COVID-19

A provocative paper from Duke-NUS Medical School, published in the Journal of Experimental Medicine in March 2020, discusses the possibilities of creating new receptors on a sick person's own immune cells as a means of controlling the infection. This therapy is already being used to treat certain cancers with marked success.

22 Apr 2020

Scientists identify cells likely targeted by novel coronavirus

Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

22 Apr 2020

New database of 14,000 known macrolactones could support drug discovery and research

Researchers from North Carolina State University and Collaborations Pharmaceuticals have created a free-to-use database of 14,000 known macrolactones - large molecules used in drug development - which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.

22 Apr 2020

Researchers are exploring potential therapy for controlling infectious diseases

The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School (Duke-NUS), as a potential therapy for controlling infectious diseases, including the COVID-19-causing virus, SARS-CoV-2.

22 Apr 2020

A new, potential treatment for nonalcoholic steatohepatitis with fibrosis

In the 2020 April 21 issue of Journal of Hepatology, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that a new insight into the pathophysiology of human nonalcoholic steatohepatitis (NASH) with fibrosis and suggested a possibility of the new therapy using cytoglobin (CYGB) inducer for clinical application.

21 Apr 2020

Greater occurrence of infections correlates with future cancer diagnosis

Patients experienced a greater occurrence of infections in the years preceding a cancer diagnosis.

17 Apr 2020

Gold-containing drug auranofin kills 95% of SARS-CoV-2 virus in 48 hours in lab conditions

A drug called auranofin, approved for the treatment of rheumatoid arthritis, effectively inhibits severe acute respiratory syndrome coronavirus (SARS-CoV-2) in laboratory conditions, as described in a new study by Georgia State University researchers.

16 Apr 2020

Specialized proteins could soak up excess cytokines in COVID-19 patients

One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also called a cytokine storm, damages the lungs and can be fatal.

16 Apr 2020

With federal nod, consumers could lose the boost they get from drug ‘coupons’

Patients who get financial help from drug companies to cover their copayments for prescription drugs could owe a bigger chunk of their costs under a proposed federal rule.

16 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

New vaccine for Chikungunya reported safe and well-tolerated

A virus-like particle vaccine was shown to be safe and well-tolerated among a healthy adult population living in chikungunya endemic areas, the researchers report in a new study published in the Journal of the American Medical Association (JAMA).

14 Apr 2020

Ebola drug effective against key enzyme of coronavirus that causes COVID-19

Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.

13 Apr 2020

Cost of ‘repurposing’ existing drugs to treat COVID-19

The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for COVID-19 at low prices globally.

13 Apr 2020

Rockefeller and SNF announce $3 million expansion of partnership for COVID-19 research

The Rockefeller University and the Stavros Niarchos Foundation today announced a $3 million expansion of their longstanding partnership for research and medicine, bolstering Rockefeller's round-the-clock research initiatives related to COVID-19 and the SARS-CoV-2 virus that causes it.

13 Apr 2020

Many of Washington State’s illicit drug users want to reduce use

A new survey of people who inject illicit drugs in the state of Washington yields positive and important findings for policy makers as the world struggles to deal with the COVID-19 pandemic, said authors of the survey by the University of Washington and Public Health-Seattle & King County.

11 Apr 2020